Log in
Enquire now
‌

US Patent 10336818 Fc variants with altered binding to FcRn

Patent 10336818 was granted and assigned to Xencor on July, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
Xencor
Xencor
Date Filed
August 13, 2014
Date of Patent
July 2, 2019
Patent Applicant
Xencor
Xencor
Patent Application Number
14459160
Patent Citations Received
‌
US Patent 12110324 Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
0
‌
US Patent 11993644 Antigen binding molecules targeting SARS-CoV-2
0
‌
US Patent 12103954 Heterodimeric Fc cytokines and uses thereof
0
‌
US Patent 10836825 Multispecific antibodies that target HIV GP120 and CD3
‌
US Patent 10882898 Human immunodeficiency virus neutralizing antibodies
‌
US Patent 10882907 Multispecific antibodies that target HIV GP120 and CD3
‌
US Patent 11597759 Multispecific antibodies that target HIV GP120 and CD3
‌
US Patent 11248046 Claudin 6 antibodies and uses thereof
‌
US Patent 11254736 Antibodies comprising a common light chain and uses thereof
‌
US Patent 11655285 Human immunodeficiency virus neutralizing antibodies
0
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10336818
Patent Primary Examiner
‌
Chun W Dahle

Find more entities like US Patent 10336818 Fc variants with altered binding to FcRn

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.